Abstract
It has long been recognised that high circulating levels of cholesterol are associated with the development of cardiovascular disease. With the discovery of the cholesterol biosynthetic pathway in 1950, it was soon realised that blockade of key conversions in this pathway may provide useful therapeutic targets for the management of hypercholesterolaemia. In the 1970s the first useful inhibitors of cholesterol biosynthesis were isolated, and paved the way for what would become a multimillion dollar pharmaceutical industry. Modern-day statins are incredibly effective hypolipidaemic agents, interrupting cholesterol biosynthesis at the rate-limiting step through a competitive inhibition mechanism. These compounds’ structures interact with key amino acid residues through a variety of defined bonding interactions, and by understanding how these interactions form, better, and safer, hypolipidaemic agents were found. This review describes the historical development of statins and brings us up-to-date with current structure-activity relationships between statins and their target enzyme.
Keywords: Cardiovascular disease, Cholesterol, HMG-CoA reductase, Hypercholesterolaemia, Lipoproteins.
Mini-Reviews in Medicinal Chemistry
Title:From fungus to pharmaceuticals – the chemistry of statins
Volume: 12 Issue: 12
Author(s): P.A.C. McPherson
Affiliation:
Keywords: Cardiovascular disease, Cholesterol, HMG-CoA reductase, Hypercholesterolaemia, Lipoproteins.
Abstract: It has long been recognised that high circulating levels of cholesterol are associated with the development of cardiovascular disease. With the discovery of the cholesterol biosynthetic pathway in 1950, it was soon realised that blockade of key conversions in this pathway may provide useful therapeutic targets for the management of hypercholesterolaemia. In the 1970s the first useful inhibitors of cholesterol biosynthesis were isolated, and paved the way for what would become a multimillion dollar pharmaceutical industry. Modern-day statins are incredibly effective hypolipidaemic agents, interrupting cholesterol biosynthesis at the rate-limiting step through a competitive inhibition mechanism. These compounds’ structures interact with key amino acid residues through a variety of defined bonding interactions, and by understanding how these interactions form, better, and safer, hypolipidaemic agents were found. This review describes the historical development of statins and brings us up-to-date with current structure-activity relationships between statins and their target enzyme.
Export Options
About this article
Cite this article as:
McPherson P.A.C., From fungus to pharmaceuticals – the chemistry of statins, Mini-Reviews in Medicinal Chemistry 2012; 12 (12) . https://dx.doi.org/10.2174/138955712802762103
DOI https://dx.doi.org/10.2174/138955712802762103 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sodium Intake Recommendations: A Subject that Needs to be Reconsidered
Current Hypertension Reviews Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Evaluation of in-vitro Anti Diabetic Activity of a Siddha Herbo- Mineral Drug
Current Traditional Medicine Urotensin-II Receptor Antagonists
Current Medicinal Chemistry Antimicrobial Agents-Associated with QT Interval Prolongation
Current Drug Safety Extrapulmonary Sarcoidosis: A Chameleon Disease at Imaging
Current Medical Imaging Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Cyclodextrins as Food Additives and in Food Processing
Current Nutrition & Food Science Editorial [Hot Topic: Efficient Strategies for Signalling Pathway Mining (Guest Editors: Qingfeng Chen & Baoshan Chen)]
Current Protein & Peptide Science Cardiac Telocytes
Current Stem Cell Research & Therapy Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Balancing the Risks of Thrombosis and Bleeding Following Transcatheter Aortic Valve Implantation: Current State-of-Evidence
Current Pharmaceutical Design Can Statin be a Novel Pharmacophore for Antidiabetic Activity?
Mini-Reviews in Medicinal Chemistry Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Why is the Incidence of Type 1 Diabetes Increasing?
Current Diabetes Reviews Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety